Cancer Blood Tests: Hope and Setbacks

The development of a single blood test capable of screening for numerous cancers has been a long-standing goal in oncology. Current advancements involve analyzing minute DNA fragments in blood, which are then fed into algorithms to identify potential cancer indicators. One study demonstrated a test's ability to correctly identify 13 cancers with high accuracy, including early-stage ones.

However, the largest trial to date, involving Grail's Galleri test, failed to meet its primary objective. The trial results indicated no significant reduction in advanced cancer diagnoses compared to a control group. While considered a setback, experts suggest it's premature to dismiss the trial entirely, as preliminary findings hint at earlier detection for some cancer types and a decrease in stage 4 diagnoses.

The medical community emphasizes the need for these tests to demonstrate a clear impact on patient survival before being widely adopted. For multi-cancer blood tests to become a paradigm shift, they must prove they can save lives. Grail plans to continue monitoring trial participants for up to eight years to assess any reduction in mortality.

Challenges remain, including the fact that some aggressive cancers may release detectable DNA but still prove difficult to treat even when detected early. Furthermore, as treatments improve, patients with advanced cancer are living longer, making it harder to gather definitive survival data for test efficacy within shorter trial periods. This also impacts insurance reimbursement, as FDA approval and widespread coverage are yet to be achieved.

Beyond survival data, there is interest in whether these tests can detect cancers for which no standard screening methods currently exist. While existing screenings cover common cancers, many less common but deadly types, like pancreatic cancer, are left behind. The accuracy of multi-cancer blood tests also varies significantly by cancer type.

Looking ahead, researchers are optimistic about developing newer tests that integrate multiple data sources, including protein levels and DNA fragment sizes, enhanced by AI to detect early-stage cancers, even those that shed less DNA. The ultimate future may involve a collection of blood tests, each designed to screen for specific families of cancers, rather than a single test for dozens of types.